AstraZeneca will present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80[th] American Diabetes Association (ADA) Virtual Scientific Sessions, 12-16 June 2020. The data are among 23 accepted abstracts, including four oral presentations, covering trials that showcase the depth and breadth of potential cardio, renal and metabolic benefits for patients across AstraZeneca's portfolio.

• An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF) (Abstract #271-OR)[1]
• New sub analysis from the DECLARE-TIMI 58 trial, presented orally, providing insights on Farxiga's effect on fast kidney function decline in T2D patients with established or increased risk for cardiovascular disease (Abstract #303-OR)[2]
• An analysis of the DAPA-HF trial examining if background T2D therapy impacts the benefits of Farxiga in heart failure (HF) (Abstract #1112-P)[3]
• A new analysis of the global observational DISCOVER real world evidence study, presented orally, reporting health-related quality of life factors in patients with T2D initiating a 2nd-line glucose-lowering therapy (Abstract #40-OR)[4]
• An oral presentation of new Phase II data on investigational cotadutide, a dual receptor agonist with balanced GLP-1 and glucagon activity, showing positive effect on blood glucose levels and changes in liver fat and glycogen stores in patients with T2D (Abstract #354-OR)[5]
• Brilinta (ticagrelor) data on duration of T2D, baseline HbA1c levels as well as the impact of blood sugar-lowering background therapies on outcomes in T2D patients with coronary artery disease (THEMIS diabetes subgroup) (Abstract #403-P)[6]

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: "An overwhelming majority of people with type-2 diabetes also have at least one other cardiovascular, renal or metabolic disease. The breadth and depth of data we are presenting at ADA 2020 demonstrates our commitment to developing treatment options for patients living with diabetes that go beyond glycaemic control to also protect the heart, liver and kidneys."

In addition to its robust clinical data, AstraZeneca will also present results from a global survey of more than 1,600 physicians in 18 countries examining primary care approaches and clinical inertia in the treatment of patients with T2D.

Key abstracts and other notable abstracts to be presented at ADA:

Lead author Abstract title Presentation details
Cotadutide
Robertson, Cotadutide Oral PresentationMonday, 15
D. (MEDI0382), a June17:30 - 17:45#354-OR
Dual Receptor
Agonist With
Glucagon-like
Peptide-1 and
Glucagon
Activity,
Modulates Hepatic
Glycogen and Fat
Content
Robertson, Cotadutide Poster PresentationSaturday, 13
D. (MEDI0382), A June10:00 - 11:00#951-P
Dual Receptor
Agonist With
Glucagon-like
Peptide-1 And
Glucagon
Activity, Is Well
-tolerated (<600
μG) With Robust
Effects On Blood
Glucose In
Patients With
T2DM
Laker, R.C. Cotadutide, a GLP Poster Presentation Saturday, 13
-1/Gcg Receptor June 10:00 - 11:00     #1800-P
Co-agonist
Improves Insulin
Sensitivity and
Restores Normal
Insulin Secretory
Capacity in DIO
Mice
Farxiga
Inzucchi, Effect of Oral PresentationMonday, 15
SE. Dapagliflozin on June8:00 - 8:15#271-OR
the Incidence Of
Diabetes: A
Prespecified
Exploratory
Analysis From
DAPA-HF
Raz, I. Effect of Oral PresentationMonday, 15
Dapagliflozin on June14:30 - 14:45#303-OR
Risk for Fast
Decline in eGFR:
Analyses from the
DECLARE-TIMI 58
Trial
Cahn, A. Cardiorenal Poster PresentationSaturday, 13
Outcomes with June10:00 - 11:00#1101-P
Dapagliflozin by
Baseline Glucose
Lowering Agents
Analyses from
DECLARE-TIMI 58
Ang, L. Dapagliflozin and Poster PresentationSaturday, 13
Measures of June10:00 - 11:00#554-P
Cardiovascular
Autonomic
Function in
Patients with
Type 2 Diabetes
Ono, S. Effects of Long Poster PresentationSaturday, 13
-term June10:00 - 11:00 #1106-P
Dapagliflozin
Treatment on
Hemorheology (D
-PATH Study)
Docherty, Does Background Poster PresentationSaturday, 13
KF. T2D Therapy June10:00 - 11:00#1112-P
Modify the
Benefits of
Dapagliflozin in
Heart Failure?
Analysis of the
DAPA-HF Trial
Sato, D. Dapagliflozin Poster PresentationSaturday, 13
Suppresses June
Adipose Fatty 10:00 - 11:00#1946-P
Acid Accumulation
in Rats Fed on
High-Fat Diet but
not on Normal
Chow
Faerch, K. Changes in Plasma Poster PresentationSaturday, 13
Levels of Liver June10:00 - 11:00#845-P
Enzymes in
Response to
Dapagliflozin,
Metformin or
Exercise in
People with
Prediabetes: The
PRE-D Trial
Clemmensen, Effects Of Poster PresentationSaturday, 13
KKB. Dapagliflozin, June10:00 - 11:00#844-P
Metformin Or
Exercise On
Plasma Glucagon
Concentrations in
Individuals With
Prediabetes: The
PRE-D Trial
Kabir, M. Dapagliflozin Poster PresentationSaturday, 13
Promotes Adipose June10:00 - 11:00#1711-P
Beiging and
Lipolysis and
Reduces Adipocyte
Size in the Obese
Prediabetic Dog
Brunton, S. Approaches to and Poster PresentationSaturday, 13
  Inertia in June10:00 - 11:00 #1188-P
Cardiovascular
and Renal Risk
Management of
Type 2 Diabetes
Patients in
Primary Care:
Global
Quantitative
Survey Results
DISCOVER
Bonnet, F. HbA1c < 7.0% Poster PresentationSaturday, 13
6 Months after June10:00 - 11:00#1598-P
Initiation of
Second-Line
Therapy in
Patients with
Uncontrolled Type
2 Diabetes is
Associated with
Good Glycemic
Control at
3 Years: The
DISCOVER Study
Nicolucci, Quality of Life Oral PresentationFriday, 12
A. in People with June18:00 - 18:15#40-OR
Type 2 Diabetes
Following
Initiation of
Second-Line
Therapy: DISCOVER
Khunti, K. Effects of Second Poster PresentationSaturday, 13
-Line Metformin June10:00 - 11:00#1590-P
Combination
Therapies on
Weight, HbA1c,
and Risk of
Hypoglycemia over
3 Years: The
DISCOVER Study
Bydureon
Clegg, LE. Once-Weekly Poster PresentationSaturday, 13
Exenatide Effects June10:00 - 11:00#958-P
on eGFR Slope and
UACR as a
Function of
Baseline UACR: An
EXSCEL Trial Post
Hoc Analysis
Brilinta
Leiter, LA. Impact of Poster PresentationSaturday, 13
Diabetes-Related June10:00 - 11:00#403-P
Factors And
Background
Antihyperglycemic
Therapy On The
Efficacy And
Safety Of
Ticagrelor Added
To Aspirin:
Insights From The
THEMIS Trial
Early
Research &
Development
Mather, K. A Direct AMPK Poster PresentationSaturday, 13
Activator Reduces June10:00 - 11:00#1820-P
Liver Steatosis
in a Mouse Model
of NASH
Cheng, W. Synergetic and Late-Breaking Poster
Distinct Roles in PresentationSaturday, 13 June10:00
the Control of - 11:00#196-LB
Food Intake and
Energy Balance
for
Subpopulations of
NTS Neurons
Gray, SM. Discrepancy Poster PresentationSaturday, 13
between Single June10:00 - 11:00#2113-P
-Cell RNA
Sequencing and
Protein
Expression
Assessments of
GLP-1Rr
Heterogeneity in
Beta Cells
Gray, SM. Quantification of Poster PresentationSaturday, 13
GLP-1R June10:00 - 11:00#2114-P
Trafficking in
Primary Beta
Cells in Response
to Different
Ligands

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM) together forms one of AstraZeneca's three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Contacts

For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).

References

1. Inzucchi SE et al. Effect of Dapagliflozin on the Incidence Of Diabetes: A Prespecified Exploratory Analysis From DAPA-HF. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
2. Raz I et al. Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analyses from the DECLARE-TIMI 58 Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
3. Docherty KF et al. Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
4. Nicolucci A et al. Quality of Life in People with Type 2 Diabetes Following Initiation of Second-Line Therapy: DISCOVER. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
5. Robertson D et al. Cotadutide (MEDI0382), a Dual Receptor Agonist With Glucagon-like Peptide-1 and Glucagon Activity, Modulates Hepatic Glycogen and Fat Content. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
6. Leiter La et al. Impact of Diabetes-Related Factors And Background Antihyperglycemic Therapy On The Efficacy And Safety Of Ticagrelor Added To Aspirin: Insights From The THEMIS Trial. Presented at: 80th American Diabetes Association Virtual Scientific Sessions, 2020 June 12-16.
7. Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000-3.